|
JP2009526761A
(ja)
*
|
2006-01-30 |
2009-07-23 |
アレイ バイオファーマ、インコーポレイテッド |
ヘテロ二環式チオフェン化合物および使用の方法
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
ES2609912T3
(es)
*
|
2007-06-22 |
2017-04-25 |
Hydra Biosciences, Inc. |
Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1
|
|
GB0722055D0
(en)
*
|
2007-11-09 |
2007-12-19 |
Argenta Discovery Ltd |
Compounds
|
|
NZ585298A
(en)
*
|
2007-11-16 |
2012-08-31 |
Rigel Pharmaceuticals Inc |
Carboxamide, sulfonamide and amine compounds for metabolic disorders
|
|
RU2492167C2
(ru)
*
|
2007-12-18 |
2013-09-10 |
Актелион Фармасьютиклз Лтд |
Производные аминотриазола в качестве агонистов alх
|
|
EA201001030A1
(ru)
|
2007-12-19 |
2011-02-28 |
Амген Инк. |
Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
|
|
JP5328816B2
(ja)
|
2008-02-22 |
2013-10-30 |
エフ．ホフマン−ラ ロシュ アーゲー |
アミロイドβの調節薬
|
|
WO2009119088A1
(ja)
*
|
2008-03-25 |
2009-10-01 |
武田薬品工業株式会社 |
複素環化合物
|
|
US8389533B2
(en)
|
2008-04-07 |
2013-03-05 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
|
WO2009140517A1
(en)
|
2008-05-14 |
2009-11-19 |
Hydra Biosciences, Inc. |
Compounds and compositions for treating chemical warfare agent-induced injuries
|
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
WO2011036885A1
(ja)
*
|
2009-09-25 |
2011-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2011036889A1
(ja)
*
|
2009-09-25 |
2011-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
US8486967B2
(en)
*
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
RU2012146246A
(ru)
*
|
2010-03-31 |
2014-05-10 |
Актелион Фармасьютиклз Лтд |
Антибактериальные производные изохинолин-3-илмочевины
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2012005805A1
(en)
*
|
2010-05-07 |
2012-01-12 |
Glaxosmithkline Llc |
Azaindazoles
|
|
US9290499B2
(en)
|
2010-05-19 |
2016-03-22 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
WO2012064744A2
(en)
|
2010-11-08 |
2012-05-18 |
Lycera Corporation |
Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
EA026115B1
(ru)
|
2010-12-17 |
2017-03-31 |
Ф. Хоффманн-Ля Рош Аг |
Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
EP2681215B1
(en)
|
2011-02-28 |
2015-04-22 |
Array Biopharma, Inc. |
Serine/threonine kinase inhibitors
|
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
EP2937349B1
(en)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
|
AR088729A1
(es)
|
2011-03-29 |
2014-07-02 |
Actelion Pharmaceuticals Ltd |
Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
|
|
US9187462B2
(en)
|
2011-08-04 |
2015-11-17 |
Array Biopharma Inc. |
Substituted quinazolines as serine/threonine kinase inhibitors
|
|
PL2748166T3
(pl)
|
2011-08-23 |
2019-05-31 |
Asana Biosciences Llc |
Związki pirimido-pirydazynonowe oraz ich zastosowanie
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
MX2014004086A
(es)
|
2011-10-03 |
2014-09-22 |
Univ North Carolina |
Compuestos de pirrolopirimidina para el tratamiento del cancer.
|
|
GB201118675D0
(en)
*
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
DK2820009T3
(en)
|
2012-03-01 |
2018-04-16 |
Array Biopharma Inc |
Serine / threonine kinase inhibitors
|
|
NZ631258A
(en)
|
2012-04-25 |
2016-11-25 |
Takeda Pharmaceuticals Co |
Nitrogenated heterocyclic compound
|
|
WO2013169704A2
(en)
|
2012-05-08 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
JP6242868B2
(ja)
|
2012-05-08 |
2017-12-06 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
|
|
AU2013266438B2
(en)
|
2012-05-22 |
2017-09-07 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
WO2014010732A1
(ja)
|
2012-07-13 |
2014-01-16 |
武田薬品工業株式会社 |
複素環化合物
|
|
TWI616430B
(zh)
*
|
2012-07-27 |
2018-03-01 |
百健Ｍａ公司 |
Ａｔｘ調節劑
|
|
JP6374384B2
(ja)
*
|
2012-08-07 |
2018-08-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
EP2882722B1
(en)
|
2012-08-13 |
2016-07-27 |
Takeda Pharmaceutical Company Limited |
Quinoxaline derivatives as gpr6 modulators
|
|
TW201408658A
(zh)
*
|
2012-08-27 |
2014-03-01 |
Array Biopharma Inc |
絲胺酸／酥胺酸激酶抑制劑
|
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
WO2014047392A1
(en)
|
2012-09-21 |
2014-03-27 |
Bristol-Myers Squibb Company |
Fluoroalkyl-1,4-benzodiazepinone compounds
|
|
CN105308030A
(zh)
|
2012-09-21 |
2016-02-03 |
百时美施贵宝公司 |
烷基、氟烷基-1,4-苯并二氮杂*酮化合物
|
|
WO2014044846A1
(en)
|
2012-09-24 |
2014-03-27 |
Evotec (Uk) Ltd. |
3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
|
|
EP2909211A4
(en)
|
2012-10-17 |
2016-06-22 |
Univ North Carolina |
PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
|
WO2014060381A1
(de)
*
|
2012-10-18 |
2014-04-24 |
Bayer Cropscience Ag |
Heterocyclische verbindungen als schädlingsbekämpfungsmittel
|
|
EP2925752A4
(en)
|
2012-11-27 |
2016-06-01 |
Univ North Carolina |
PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EP2956138B1
(en)
|
2013-02-15 |
2022-06-22 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
MX368903B
(es)
|
2013-02-20 |
2019-10-21 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
|
|
EP2975031A4
(en)
|
2013-03-14 |
2017-04-19 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
CN104098563A
(zh)
*
|
2013-04-02 |
2014-10-15 |
山东亨利医药科技有限责任公司 |
Jnk抑制剂化合物
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3018123B1
(en)
|
2013-07-03 |
2023-05-10 |
Takeda Pharmaceutical Company Limited |
Amide compound
|
|
JP6427491B2
(ja)
|
2013-07-03 |
2018-11-21 |
武田薬品工業株式会社 |
複素環化合物
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
JPWO2015012328A1
(ja)
|
2013-07-24 |
2017-03-02 |
武田薬品工業株式会社 |
複素環化合物
|
|
CN105828822B
(zh)
|
2013-08-14 |
2019-10-18 |
诺华股份有限公司 |
用于治疗癌症的组合疗法
|
|
US9458169B2
(en)
|
2013-11-01 |
2016-10-04 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
WO2015083833A1
(ja)
*
|
2013-12-06 |
2015-06-11 |
カルナバイオサイエンス株式会社 |
新規キナゾリン誘導体
|
|
US9783511B2
(en)
|
2013-12-20 |
2017-10-10 |
Lycera Corporation |
Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
|
|
JO3466B1
(ar)
|
2013-12-20 |
2020-07-05 |
Takeda Pharmaceuticals Co |
مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
|
|
US9809561B2
(en)
|
2013-12-20 |
2017-11-07 |
Merck Sharp & Dohme Corp. |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
|
WO2015095788A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
RU2016134751A
(ru)
|
2014-01-29 |
2018-03-02 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Соединения
|
|
MA39219B1
(fr)
|
2014-01-29 |
2018-11-30 |
Glaxosmithkline Ip Dev Ltd |
Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
|
|
WO2015123505A1
(en)
|
2014-02-14 |
2015-08-20 |
Takeda Pharmaceutical Company Limited |
Pyridopyrazines modulators of gpr6
|
|
JP2017507950A
(ja)
|
2014-02-27 |
2017-03-23 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
HRP20210319T1
(hr)
|
2014-03-26 |
2021-04-30 |
Astex Therapeutics Ltd. |
Kombinacije inhibitora fgfr i inhibitora igf1r
|
|
RU2715236C2
(ru)
|
2014-03-26 |
2020-02-26 |
Астекс Терапьютикс Лтд |
Комбинации
|
|
US9555031B2
(en)
|
2014-04-11 |
2017-01-31 |
The University Of North Carolina At Chapel Hill |
Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP6523337B2
(ja)
|
2014-05-05 |
2019-05-29 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
|
|
EP3140291A4
(en)
|
2014-05-05 |
2018-01-10 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
|
TR201809990T4
(en)
|
2014-05-09 |
2018-08-27 |
Pimera Inc |
NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING.
|
|
US9758518B2
(en)
|
2015-03-04 |
2017-09-12 |
Pimera, Inc. |
Compositions, uses and methods for making them
|
|
CN105294682B
(zh)
|
2014-07-26 |
2017-07-07 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
BR112017013440A2
(pt)
|
2014-12-24 |
2018-01-09 |
Gilead Sciences, Inc. |
compostos de isoquinolina para o tratamento de hiv
|
|
SG11201705192PA
(en)
|
2014-12-24 |
2017-07-28 |
Gilead Sciences Inc |
Fused pyrimidine compounds for the treatment of hiv
|
|
TWI699355B
(zh)
|
2014-12-24 |
2020-07-21 |
美商基利科學股份有限公司 |
喹唑啉化合物
|
|
EP3253390B1
(en)
|
2015-02-06 |
2022-04-13 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as a2a antagonist
|
|
TWI719960B
(zh)
|
2015-02-10 |
2021-03-01 |
英商阿斯迪克治療公司 |
新穎組成物
|
|
CA2975997A1
(en)
|
2015-02-11 |
2016-08-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
US10421751B2
(en)
|
2015-05-05 |
2019-09-24 |
Lycera Corporation |
Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
AU2016276947A1
(en)
|
2015-06-11 |
2017-12-14 |
Lycera Corporation |
Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
|
EP3353164B1
(en)
|
2015-09-23 |
2021-11-03 |
Janssen Pharmaceutica, N.V. |
Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
|
|
US11155555B2
(en)
|
2015-09-23 |
2021-10-26 |
Janssen Pharmaceutica Nv |
Compounds
|
|
US10344000B2
(en)
|
2015-10-27 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
|
|
JP2018535958A
(ja)
|
2015-10-27 |
2018-12-06 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
|
|
EP3368535B1
(en)
|
2015-10-27 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
|
|
US9630968B1
(en)
|
2015-12-23 |
2017-04-25 |
Arqule, Inc. |
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
|
GB201604647D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
AR108326A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
EP3464270B1
(en)
*
|
2016-05-24 |
2022-02-23 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
|
|
WO2017201585A1
(en)
*
|
2016-05-26 |
2017-11-30 |
Genea Ip Holdings Pty Ltd |
Modulators of dux4 for regulation of muscle function
|
|
JP6970126B2
(ja)
*
|
2016-06-02 |
2021-11-24 |
セルジーン コーポレイション |
動物及びヒトの抗マラリア薬
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
TW201811795A
(zh)
|
2016-08-24 |
2018-04-01 |
美商亞闊股份有限公司 |
胺基－吡咯并嘧啶酮化合物及其用途
|
|
AU2017324713B2
(en)
|
2016-09-08 |
2020-08-13 |
KALA BIO, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
US10336767B2
(en)
|
2016-09-08 |
2019-07-02 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP3509423A4
(en)
|
2016-09-08 |
2020-05-13 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
EP3601286A4
(en)
|
2017-03-28 |
2020-09-23 |
Pimera, Inc. |
NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
|
|
EP3601259B1
(en)
|
2017-03-30 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Isoquinolines as inhibitors of hpk1
|
|
CN118105392A
(zh)
|
2017-04-28 |
2024-05-31 |
自由生物有限公司 |
治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
|
US10604514B2
(en)
*
|
2017-10-19 |
2020-03-31 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
|
WO2019084496A1
(en)
*
|
2017-10-27 |
2019-05-02 |
Samumed, Llc |
6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL- (HETEROARYL 5-CHAIN) CARBOXAMIDES, PREPARATION AND USE
|
|
WO2019084497A1
(en)
|
2017-10-27 |
2019-05-02 |
Samumed, Llc |
6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
|
|
US10703748B2
(en)
|
2017-10-31 |
2020-07-07 |
Samumed, Llc |
Diazanaphthalen-3-yl carboxamides and preparation and use thereof
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
TW202019905A
(zh)
*
|
2018-07-24 |
2020-06-01 |
瑞士商赫孚孟拉羅股份公司 |
異喹啉化合物及其用途
|
|
TW202024053A
(zh)
*
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
US11612606B2
(en)
|
2018-10-03 |
2023-03-28 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
BR112021005733A2
(pt)
|
2018-10-17 |
2021-07-27 |
Array Biopharma Inc. |
inibidores de proteína tirosina fosfatase
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021004547A1
(en)
*
|
2019-07-11 |
2021-01-14 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of hpk1
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
TW202140473A
(zh)
|
2020-01-15 |
2021-11-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
|
WO2021257863A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Pyrrolotriazine compounds as jak2 v617f inhibitors
|
|
US11691971B2
(en)
|
2020-06-19 |
2023-07-04 |
Incyte Corporation |
Naphthyridinone compounds as JAK2 V617F inhibitors
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
CR20230057A
(es)
|
2020-07-02 |
2023-08-15 |
Incyte Corp |
Compuestos tríciclicos de urea como inhibidores de jak2 v617f
|
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
KR20230104781A
(ko)
|
2020-10-05 |
2023-07-10 |
인라이븐 테라퓨틱스, 인크. |
Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
|
|
CN114380752A
(zh)
*
|
2020-10-22 |
2022-04-22 |
南开大学 |
一种制备n-取代-2，4-喹唑啉二酮类化合物的合成方法
|
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|
|
AR125273A1
(es)
|
2021-02-25 |
2023-07-05 |
Incyte Corp |
Lactamas espirocíclicas como inhibidores de jak2 v617f
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN115583946B
(zh)
*
|
2021-07-06 |
2026-01-16 |
赛诺哈勃药业（成都）有限公司 |
杂环化合物及其作为cdk抑制剂的用途
|
|
WO2023288254A1
(en)
|
2021-07-14 |
2023-01-19 |
Blueprint Medicines Corporation |
Heterocyclic compounds as map4k1 inhibitors
|
|
PT4426434T
(pt)
|
2021-11-02 |
2025-11-24 |
Flare Therapeutics Inc |
Agonistas inversos de pparg e suas utilizações
|
|
WO2023126951A1
(en)
|
2022-01-03 |
2023-07-06 |
Yeda Research And Development Co. Ltd. |
Inhibitors of autophagy-related protein-protein interactions
|
|
AU2023235313A1
(en)
|
2022-03-17 |
2024-10-03 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
|
CN116731030B
(zh)
*
|
2023-06-07 |
2026-03-31 |
湖北医药学院 |
几种呋喃并嘧啶-布洛芬杂合衍生物的合成方法及抗肿瘤的应用
|
|
AU2024290917A1
(en)
*
|
2023-07-03 |
2026-01-22 |
Cervero Therapeutics, LLC |
Polo-like kinase 1 inhibitors
|